banner-risc-cardiovascular

Proyectos

Patologia Visual en Nens

  • IP: Bonaventura Bolíbar Ribas
  • Duración: 2015-2015

– Codi H50: Estrabisme, des del subapartat H50.0 fins al H50.5
– Codi H52: Transtorns de la refracció i l’acomodació, des del subapartat H52.0 al H52.2
– Codi H53: Alteracions visuals, concretament els subapartats H53.0 i H53.5
– Codi H54: Ceguesa i visió disminuïda
– Codi Q12.0: Cataracta congènita

Agomelatina 2

  • IP: Rosa Morros Pedrós
  • Duración: 2015-2015

Preliminary Feasibility Study: A Randomized, Event Driven, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin on the Development of Type 2 Diabetes Mellitus (T2DM) in Subjects with prediabetes

  • IP: Ernest Vinyoles Bargalló
  • Duración: 2016-2023
  • Financiadores: Janssen - Cilag, S.A.

MPOC

  • IP: Mònica Monteagudo Zaragoza
  • Duración: 2016-2016

Morbidity incidence rates for health impact assessment study

  • IP: Talita Duarte Salles
  • Duración: 2016-2016
  • Financiadores: Fundación Privada Instituto de Salud Global Barcelona (ISGlobal)

Introduction: Until now, estimates of the Global Burden of Disease have mainly been produced on national or regional levels. These estimates, however, are less useful for city governments who have to take decisions on local scales. We conducted a burden of disease (BoD) assessment and applied the Urban and Transport Planning Health Impact Assessment (UTOPHIA) tool to estimate annual preventable morbidity by complying with international exposure recommendations for the performance of physical activity, exposure to air pollution, noise, heat and access to green spaces in Barcelona.
Methods: Exposure estimates and morbidity data were available for 1357361 Barcelona residents ?20 years. We compared recommended with current exposure levels. We quantified the associations between exposures and morbidity and calculated population attributable fractions to estimate the number of morbidity cases. We also quantified the BoD attributable to non-compliant exposure levels by calculating disability-adjusted life-years (DALYs).
Results: Our estimations show that a large morbidity burden is attributable to current urban and transport planning practices in Barcelona. Non-compliance of recommended exposure levels for physical activity, air pollution, noise, heat and access to green spaces were estimated to generate almost 40,000 DALYs annually. Almost 50% of the BoD was due to road traffic noise with especially sleep disturbance and annoyance contributing largely.
Conclusions: The estimated BoD could be modified by changes to urban and transport planning related practices. We emphasize the need for (1) the reduction of motorized traffic and (2) the provision of green infrastructure to provide mitigation of noise, air pollution and heat as well as opportunities for physical activity engagement.

Dulaglutide Viabilitat

  • IP: Mª del Mar Garcia Gil
  • Duración: 2016-2017
  • Financiadores: IQVIA Information, S. A.

Antibiotics – Julius Clinical

  • IP: Ernest Vinyoles Bargalló
  • Duración: 2016-2016

– Nombre de pacients >50 anys a qui se?ls ha prescrit almenys un antibiòtic en les darreres 12 setmanes? (tots els codis ATC J01)
– Nombre total de pacients >50 anys

Patrons d’ús i efectivitat a llarg termini dels inhibidors de la PCSK9.

  • IP: Mª del Mar Garcia Gil
  • Duración: 2016-2016
  • Financiadores: Institut d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol)

Assaig Clínic HTA i danys substància gris. Estudi ISIS

  • IP: Ernest Vinyoles Bargalló
  • Duración: 2017-2020
  • Financiadores: Institut d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol)

ROADS – Estudi de Viabilitat

  • IP: Rafel Ramos Blanes
  • Duración: 2017-2020